The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Celsion is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of CLSN and the rest of the Medical group's stocks.
Celsion is a member of the Medical sector. This group includes 844 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CLSN is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for CLSN's full-year earnings has moved 17.02% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CLSN has returned 53.19% so far this year. Meanwhile, the Medical sector has returned an average of 3.81% on a year-to-date basis. This shows that Celsion is outperforming its peers so far this year.
Breaking things down more, CLSN is a member of the Medical - Biomedical and Genetics industry, which includes 352 individual companies and currently sits at #78 in the Zacks Industry Rank. On average, stocks in this group have gained 3.54% this year, meaning that CLSN is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CLSN as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Celsion is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of CLSN and the rest of the Medical group's stocks.
Celsion is a member of the Medical sector. This group includes 844 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. CLSN is currently sporting a Zacks Rank of #1 (Strong Buy).
Within the past quarter, the Zacks Consensus Estimate for CLSN's full-year earnings has moved 17.02% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CLSN has returned 53.19% so far this year. Meanwhile, the Medical sector has returned an average of 3.81% on a year-to-date basis. This shows that Celsion is outperforming its peers so far this year.
Breaking things down more, CLSN is a member of the Medical - Biomedical and Genetics industry, which includes 352 individual companies and currently sits at #78 in the Zacks Industry Rank. On average, stocks in this group have gained 3.54% this year, meaning that CLSN is performing better in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to CLSN as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>